LINC00052 and breast carcinoma: Similarly, our research group showed that LINC00052 is associated with improved overall survival in breast cancer patients and that LINC00052 inhibits BC cell migration through modulation of the cytoskeleton and NOTCH/β–catenin/NFkB signalling pathways [20].